Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy may cut need for frequent eye shots in macular degeneration

NCT ID NCT00527475

Disease control Sponsor: Texas Retina Associates Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a light-based treatment (photodynamic therapy) to the standard drug ranibizumab could reduce the number of eye injections needed for wet macular degeneration. Sixty adults over age 50 with the condition took part. The goal was to see if the combination worked as well as ranibizumab alone while requiring fewer injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Start date

May 2007

Finished

Jan 2010

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willingness to sign informed consent. 2. Age greater than 50. 3. Evidence of macular degeneration in the form of drusen in either eye. 4. Visual acuity of 20/25 to 20/800. 5. Subfoveal choroidal neovascularization. Both occult and classic subtypes will be allowed. If lesion is purely occult there has to be one of the following: 1. Recent loss of vision (5 letters on ETDRS or doubling of visual angle by snellen) 2. Documented enlargement of lesion on FA 3. Increase of 50 microns or more in the central subfield on OCT 4. New blood 6. Total active lesion must be less than 12 disc areas in size. - Exclusion Criteria: 1. Myopia, ocular histoplasmosis, or other retinal pathology that could affect vision 2. Previous treatment of the enrolled eye for CNV 3. Intraocular surgery within 6 weeks of enrollment 4. Geographic atrophy, subretinal fibrosis, or pigment epithelial tear involving the fovea of the eligible eye 5. Known hypersensitivity to verteporfin 6. Medical condition that would preclude regular follow-up for one year. 7. Previous vitrectomy 8. Media opacities limiting visual acuity, retinal examination, or retinal imaging. 9. A lesion where \> 50% of the lesion is a pigment epithelial detachment. -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

macular degeneration Neovascularization, Pathologic wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Macular degeneration

Contacts and locations

Locations

  • Associated Retinal Consultants

    Ann Arbor, Michigan, 49301, United States

  • California Retina Consultants & Research Foundation

    Santa Barbara, California, 93103, United States

  • Texas Retina Associates

    Arlington, Texas, 76012, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.